News Category
Apimeds Pharmaceuticals US, Inc. has engaged IBN to enhance its corporate communications strategy, aiming to increase visibility for its digital asset...
Regentis Biomaterials CEO Dr. Ehud Geller discussed the company's regenerative medicine platform and lead product GelrinC, which is approved in Europe...
Silo Pharma Inc. has received a Notice of Allowance from the USPTO for a patent covering its lead intranasal PTSD therapeutic SPC-15, strengthening it...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, with European approval and a U.S...
Med-X Inc. is advancing its Nature-Cide natural pest-control brand as its primary growth platform ahead of a planned Nasdaq debut, with recent OMRI ce...
Telomir Pharmaceuticals announced that its lead drug candidate Telomir-Zn inhibited growth in human and canine osteosarcoma cell lines, potentially pa...
Quantum BioPharma has received FDA clearance for its Investigational New Drug application for Lucid-MS, enabling a Phase 2 trial in multiple sclerosis...
GeoVax has secured access to CEPI's Centralised Laboratory Network for independent testing of its MVA-based mpox vaccine, aiming to diversify global v...
Tevard Biosciences and collaborators published preclinical research in Science Advances showing that engineered suppressor tRNA gene therapy restored ...
Creative Biolabs has expanded its functionalized lipid-based delivery system development capabilities to help researchers engineer more precise delive...
Creative Biolabs has expanded its single-cell multi-omics and RNA sequencing solutions to meet growing demand for high-resolution cellular profiling, ...
A comprehensive review reveals that the tumor microenvironment actively reshapes natural killer cells into distinct functional subsets, offering new o...
GeoVax Labs is appealing a Nasdaq delisting determination while continuing to advance its GEO-MVA vaccine and Gedeptin cancer therapy, highlighting th...
Regentis Biomaterials reported a narrower net loss for the first half of 2026 and progress in its pivotal U.S. trial of GelrinC, a cell-free hydrogel ...
Quantum BioPharma has received FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis candidate designed to protect ...
TransCode Therapeutics announced the immediate retirement of CFO Tom Fitzgerald and the appointment of John Tattory as interim CFO, a change that coul...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer signals a strategic push to advance its innovative BiTAC technology an...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, is moving toward a Phase 2 trial in multiple sclerosis following FDA clear...
Quantum BioPharma's Lucid-MS, the first drug designed to shield and rebuild myelin, receives FDA clearance for a Phase 2 trial, potentially transformi...
Quantum BioPharma has received FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis treatment designed to protect ...
Helus Pharma CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, providing invest...
Onco-Innovations' CMO discussed the company's lead drug candidate ONC010, which uses synthetic lethality and nanoparticle delivery to target PNKP in c...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, is moving toward a phase 2 trial in multiple sclerosis following FDA clear...
American Fusion Inc. has advanced its Texatron fusion program into active testing, achieving peak pressures of approximately 100,000 atmospheres, whil...
Kairos Pharma's CEO will present a corporate overview at a major investment conference, highlighting the company's progress in developing ENV-105 to c...
Nutriband CEO Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on Sept. 16, 2026, highlighting the company's focus on abuse-deterre...
Silo Pharma announces its participation in the IPAC-RS 2026 Nasal Innovation Forum, where it will discuss advancements in its nose-to-brain drug deliv...
Quantum BioPharma's Lucid-MS, a potential first-in-class treatment for multiple sclerosis, has received FDA clearance for Phase 2 trials, drawing a ne...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protecting drug candidate for multiple sclerosis, has received FDA clearance to begin a Phase 2 ...
Helus Pharma's CEO will discuss the company's clinical programs and progress at a major investment conference, highlighting its novel serotonergic ago...
GeoVax Labs supports the new Gavi-funded global mpox vaccine stockpile, emphasizing its GEO-MVA candidate's potential to diversify supply and strength...
Voyageur Pharmaceuticals has received a $1 million payment from Bayer after completing the first milestone in their collaboration to develop domestic ...
Greenland Mines announces a Q4 biotech spin-off, Nasdaq compliance, and acquisition of the Sarfartoq rare earths project, positioning itself as a key ...
VERAXA Biotech strengthens its leadership with the appointment of Raju Willener as CFO, bringing extensive financial expertise to support its oncology...
Scinai Immunotherapeutics refocuses its R&D portfolio after ending PC111 license, aiming to boost its NanoAb platform and CDMO business.
Onco-Innovations Ltd. has strengthened its clinical foundation for its lead candidate ONC010 through manufacturing milestones, IND-enabling activities...
OS Animal Health, a subsidiary of OS Therapies, is showcasing its HER2-targeting immunotherapy for canine osteosarcoma at the Moody Capital Solutions ...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS marks a potential breakthrough in MS treatment by targeting myelin repair, offering ...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS, a drug targeting myelin repair, marks a potential breakthrough in multiple sclerosi...
NanoViricides has registered its Phase II clinical trial for NV-387 Oral Gummies against Ebola in the Pan African Clinical Trials Registry, moving for...
Greenland Mines announces a Q4 2026 spin-off of its biotech division, Nasdaq compliance approval, and a high-value assessment for its Sarfartoq rare e...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, has received FDA clearance to begin Phase 2 testing in multiple sclerosis patients, pot...
Quantum BioPharma's FDA clearance to initiate a Phase 2 trial of Lucid-MS for multiple sclerosis marks a significant step toward a novel therapy that ...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS marks a pivotal step toward a targeted therapy for multiple sclerosis, potentially s...
The LGL Group's participation in the Moody Capital Solutions 2026 Disruptive Growth and Life Sciences Conference is highlighted, underscoring its stra...
Interlink Electronics, a leading sensor and printed electronic solutions provider, will showcase its growth strategy at the upcoming Moody Capital con...
Moody Capital Solutions’ 2026 Disruptive Growth & Life Sciences Conference aims to provide investors with insights into the converging small-cap life ...
Tonix Pharmaceuticals announced the promotion of Thomas Englese to Chief Commercial Officer, effective immediately, as the company focuses on expandin...
